Patents by Inventor Alain Razafindratsita

Alain Razafindratsita has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compositions for antigen-specific induction of tolerance
    Patent number: 10610586
    Abstract: The invention relates to an immunogenic composition for sublingual, perlingual or oral administration, comprising at least an antigen and at least an adjuvant that is a bacterium selected from a Bifidobacterium and a lactic acid bacterium, and/or a combination of a corticosteroid with vitamin D3 or any metabolite or analog of the latter, in a pharmaceutically acceptable carrier that is suitable for sublingual, perlingual, or oral administration. Such compositions allow to elicit antigen-specific immune tolerance.
    Type: Grant
    Filed: August 18, 2016
    Date of Patent: April 7, 2020
    Assignee: STALLERGENES
    Inventors: Philippe Moingeon, Laurence Van Overtvelt, Alain Razafindratsita
  • Compositions For Antigen-Specific Induction of Tolerance
    Publication number: 20170043013
    Abstract: The invention relates to an immunogenic composition far sublingual, perlingual or oral administration, comprising at least an antigen and at least an adjuvant that is a bacterium selected from a Bifidobacterium and a lactic acid bacterium, and or a combination of a corticosteroid with vitamin D3 or any metabolite or analog of the latter, in a pharmaceutically acceptable carrier that is suitable tor sublingual, perlingual, or oral administration. Such compositions allow to elicit antigen-specific immune tolerance.
    Type: Application
    Filed: August 18, 2016
    Publication date: February 16, 2017
    Inventors: Philippe MOINGEON, Laurence VAN OVERTVELT, Alain RAZAFINDRATSITA
  • Compositions for antigen-specific induction of tolerance
    Patent number: 9555102
    Abstract: The invention relates to an immunogenic composition for sublingual, perlingual or oral administration, comprising at least an antigen and at least an adjuvant that is a bacterium selected from a Bifidobacterium and a lactic acid bacterium, and/or a combination of a corticosteroid with vitamin D3 or any metabolite or analog of the latter, in a pharmaceutically acceptable carrier that is suitable for sublingual, perlingual, or oral administration. Such compositions allow to elicit antigen-specific immune tolerance.
    Type: Grant
    Filed: May 18, 2006
    Date of Patent: January 31, 2017
    Assignee: Stallergenes
    Inventors: Philippe Moingeon, Laurence Van Overtvelt, Alain Razafindratsita
  • Mucoadhesive particulate formulation for inducing antigen-specific immune tolerance
    Patent number: 9480748
    Abstract: The present disclosure relates to a mucoadhesive composition, adapted for preventing and/or treating a pathological reaction of the immune system of an individual, by inducing a specific tolerance towards at least one antigen involved in said pathological reaction, comprising chitosan particles loaded with said at least one antigen involved in the pathological reaction, wherein the size of the loaded chitosan particles is of more than 800 nm.
    Type: Grant
    Filed: November 22, 2013
    Date of Patent: November 1, 2016
    Assignee: STALLERGENES
    Inventors: Nathalie Saint-Lu, Alain Razafindratsita, Sophie Tourdot, Philippe Moingeon, Laurence Van Overtvelt
  • MUCOADHESIVE PARTICULATE FORMULATION FOR INDUCING ANTIGEN-SPECIFIC IMMUNE TOLERANCE
    Publication number: 20140079795
    Abstract: The present disclosure relates to a mucoadhesive composition, adapted for preventing and/or treating a pathological reaction of the immune system of an individual, by inducing a specific tolerance towards at least one antigen involved in said pathological reaction, comprising chitosan particles loaded with said at least one antigen involved in the pathological reaction, wherein the size of the loaded chitosan particles is of more than 800 nm.
    Type: Application
    Filed: November 22, 2013
    Publication date: March 20, 2014
    Applicant: STALLERGENES S.A.
    Inventors: Nathalie SAINT-LU, Alain RAZAFINDRATSITA, Sophie TOURDOT, Philippe MOINGEON, Laurence VAN OVERTVELT
  • MUCOADHESIVE PARTICULATE FORMULATION FOR INDUCING ANTIGEN-SPECIFIC IMMUNE TOLERANCE
    Publication number: 20110150987
    Abstract: The present invention relates to a mucoadhesive composition, adapted for preventing and/or treating a pathological reaction of the immune system of an individual, by inducing a specific tolerance towards at least one antigen involved in said pathological reaction, comprising chitosan particles loaded with said at least one antigen involved in the pathological reaction, wherein the size of the loaded chitosan particles is of more than 800 nm.
    Type: Application
    Filed: May 20, 2009
    Publication date: June 23, 2011
    Applicant: STALLERGENES S.A.
    Inventors: Nathalie Saint-Lu, Alain Razafindratsita, Sophia Tourdot, Philippe Moingeon, Laurence Van Overtvelt
  • Compositions For Antigen-Specific Induction of Tolerance
    Publication number: 20080233155
    Abstract: The invention relates to an immunogenic composition for sublingual, perlingual or oral administration, comprising at least an antigen and at least an adjuvant that is a bacterium selected from a Bifidobacterium and a lactic acid bacterium, and/or a combination of a corticosteroid with vitamin D3 or any metabolite or analog of the latter, in a pharmaceutically acceptable carrier that is suitable for sublingual, perlingual, or oral administration. Such compositions allow to elicit antigen-specific immune tolerance.
    Type: Application
    Filed: May 18, 2006
    Publication date: September 25, 2008
    Inventors: Philippe Moingeon, Laurence Van Overtvelt, Alain Razafindratsita
  • Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
    Publication number: 20060292186
    Abstract: A pharmaceutical composition in a form of an anhydrous self-nanoemulsifying oily formulation comprising: one or more therapeutic agent(s) which have low solubility in water or are water-insoluble, vitamin E, one co-solvent selected from propylene glycol and ethanol and mixture thereof one surfactant selected from tyloxapol and from mixture of tyloxapol and TPGS, and optionally, a bioenhancer.
    Type: Application
    Filed: August 27, 2004
    Publication date: December 28, 2006
    Applicant: Novagali Pharma SA
    Inventors: Jean-Sebastien Garrigue, Gregory Lambert, Alain Razafindratsita, Simon Benita, Shicheng Yang, Neslihan Gursoy
  • Self emulsifying drug delivery systems for poorly soluble drugs
    Publication number: 20050232952
    Abstract: A pharmaceutical composition in a form of a self-microemulsifying drug delivery system comprising: one or more therapeutic agent(s) which have low solubility in water or are water-insoluble, vitamin E, one co-solvent selected from propylene glycol and ethanol, one or more bile salts, TPGS, and one further surfactant selected from Tyloxapol and polyoxyl hydrogenated castor oil.
    Type: Application
    Filed: February 28, 2003
    Publication date: October 20, 2005
    Inventors: Gregory Lambert, Alain Razafindratsita, Jean-Sebastien Garrigue, Shicheng Yang, Neslihan Gursoy, Simon Benita
  • Drug delivery system
    Publication number: 20050180997
    Abstract: A combination product comprising a positive oil in water emulsion wherein said emulsion comprises a compound presenting free NH2 groups, at its natural state, at the oil-water interface, and an antibody, wherein said compound is linked to said antibody by a heterobifunctional linker, linking said NH2 groups to SH groups on the antibody hinge region.
    Type: Application
    Filed: February 27, 2004
    Publication date: August 18, 2005
    Inventors: Simon Benita, Danny Goldstein, Taher Nassar, Ola Sader, Alain Razafindratsita, Gregory Lambert, Jean Kadouche